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had sought no medical care for his symptoms until this ED 
presentation.
Upon arrival to the ED via ambulance, the patient was 
obviously anxious and avoided unnecessary movement. 
Temperature was 100.1˚F, heart rate was 145 beats per minute, 
blood pressure 124/77 mm Hg, respiratory rate 20 breaths 
per minute, with oxygen saturation 99% on room air. Heart 
tones were regularly tachycardic, free of murmurs or rubs. 
Pulmonary exam was clear to auscultation bilaterally, without 
crackles or wheezes. There was no edema of the extremities, 
no lymphadenopathy, and no hepatosplenomegaly. 
Skin exam (Figure 1) revealed diffuse regions of skin 
sloughing with necrosis and a mildly erythematous base 
along the dermis; there were occasional small bullae and 
vesicles. Over 50% of the patient’s total body surface area 
(BSA) was involved, including his back, abdomen, scrotum, 
and perirectal area. However, the forehead and scalp were 
spared. There was no purulent discharge, pustules, purpura 
or ulcerations, but a strong foul-smelling odor was noted. 
The non-affected area of the patient’s skin easily sloughed 
with lateral traction. The oral mucosa was injected and 
sloughing apparent. Conjunctivae were spared.
After the patient’s temperature increased to 101.7° F 
on repeat assessment, vancomycin and meropenem were 
administered, and blood cultures were sent. The patient 
received four liters intravenous (IV) normal saline while in 
the ED, and was made comfortable with morphine. Pertinent 
laboratory values included a white blood cell count of 12,000/
mm and a lactic acid of 2.8 mmol/L, serum bicarbonate 21 
mmol/L, serum glucose 140 mg/dL, blood urea nitrogen 9 
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Toxic epidermal necrolysis is a rare disease that is most often drug-induced but can be of idiopathic 
origin. We present a case that originated at the site of a cigarette burn to the forearm and review the key 
elements of physical exam findings and management of this life-threatening dermatological condition, 
which needs to be promptly recognized to decrease patient mortality.
[West J Emerg Med. 2010; 11(2):205-207.]
INTRODUCTION
Toxic epidermal necrolysis (TEN) is a rare entity, with 
a reported incidence of 0.4 to 1.9 cases per million person-
years.1,2 It is one of the few dermatological emergencies that 
must be promptly diagnosed in the emergency department 
(ED). The disorder is typically drug-induced, with the most 
commonly cited agents including sulfonamide antibiotics, 
oxicam non-steroidal anti-inflammatory drugs (NSAIDs), 
anticonvulsants, and allopurinol.3 Various other precipitants 
have been reported, including food additives, fumigants and 
chemical contacts, aerosolized pentamadine and graft-versus-
host disease.1,2,4 We describe a case of TEN that originated at 
the site of a cigarette burn to the forearm.
CASE REPORT
A 31-year-old black male with no significant past 
medical history presented to the ED at his family’s insistence, 
complaining of open sores covering his body. The patient 
recalled the sores began at the site of a cigarette burn to his 
left forearm two weeks prior to presentation, and subsequently 
spread diffusely over the body. The lesions were slightly 
tender to the touch. Review of systems was negative for a viral 
prodrome, and the patient denied any fevers, chills, or sweats. 
He denied any chest pain or shortness of breath, and there had 
been no abdominal pain, nausea or vomiting. There was no 
history of ill contacts, animal exposure, insect bites or recent 
travel. The patient denied intravenous drug use, but admitted 
to chronic use of tobacco, alcohol and marijuana. The patient 
reported he had not been taking any medications, denied any 
known allergies, and denied any significant family history. He Volume XI, no. 2  :  May 2010             206  Western Journal of Emergency Medicine
mg/dL, creatinine 0.9 mg/dL and anion gap 10 mmol/L. The 
patient remained stable, although persistently tachycardic, and 
was admitted to the intensive care unit.
He subsequently developed severe sepsis, and 
blood cultures returned positive for oxacillin-sensitive 
Staphylococcal aureus. Per recommendation of the 
dermatology consultant, the patient was empirically started on 
steroids and received intravenous immunoglobulin (IVIG). He 
was cared for in the Burn Care Unit and underwent multiple 
surgical debridement procedures. Skin biopsy revealed 
“non-specific epidermal necrosis, consistent with TEN,” 
according to the pathologist, although further specifics of the 
histopathology were not described. The patient was ultimately 
discharged home after a protracted hospital stay.
DISCUSSION
While the pathophysiology of TEN is unclear, 
immunologic and metabolic etiologies have been theorized.5 
TEN is currently considered an extreme form of a continuum 
of disease, which includes Stevens-Johnson Syndrome (SJS) 
and erythema multiforme, although there is debate regarding 
inclusion of the latter.6,7 There is a significant associated 
mortality rate, ranging between 30-50%, largely due to 
secondary infection and multi-organ dysfunction syndrome.3,6 
The cutaneous involvement of TEN is classically 
characterized by regions of confluent erythema with extensive 
blistering and desquamation, encompassing >30% of total 
body surface area (BSA); the scalp is characteristically 
spared.1,2,8 The disease is often preceded by a viral syndrome, 
followed by a central-to-peripheral spreading macular 
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Figure 1 Cutaneous desquamation of the face (left) and the back (right), with a 10cm ruler for scale. 
exanthem.2,3 Mucous membrane involvement is generally 
present and can potentially lead to respiratory distress.1-3 
Due to epidermolysis, a positive Nikolsky’s sign (shearing 
of epidermis from dermis with light manual traction) is 
universally present.1,2,6,9
Once the diagnosis is suspected, key elements of 
management include cessation of the offending agent, 
supportive care, and transfer to a regional burn care center.3,6 
Airway-protective considerations must be taken into account, 
as tracheal and bronchial sloughing may cause obstruction.3 
While fluid management is vital in TEN, it differs from 
thermal injury management since there tends to be a smaller 
overall fluid loss due to a lesser systemic inflammatory 
response and a smaller degree of capillary permeability.6,10 
No current gold-standard formula exists to calculate fluid 
resuscitation, but titrating IV crystalloid to achieve a urine 
output ≥0.5 mL/kg/hr is reasonable. Exposed dermis should 
be covered to decrease the risk of infection; however, 
prophylactic antibiotics are not routinely recommended and 
can potentially complicate the clinical course by selecting 
resistant organisms.2,3,6 Early transfer of patients with TEN 
to a burn care center, after initial stabilization, has shown 
to reduce mortality.11 A validated severity-of-illness scoring 
system (SCORTEN), consisting of seven variables, has been 
developed to predict the mortality risk (Table 1).12
A definitive abortive treatment of TEN has yet to be 
established. Several different treatment modalities have 
been used with varying degrees of success, including 
corticosteroids, thalidomide, plasmapheresis, and IVIG; few 
of these are practical for use in the ED.13-18Volume XI, no. 2  :  May 2010             207  Western Journal of Emergency Medicine
CONCLUSION
In this patient, the temporal and physical relationship of 
the cigarette burn to the onset of symptoms was suggestive 
that this may have been the inciting event. However, upon 
further questioning during his hospitalization, he admitted to 
over-the-counter NSAID use sometime prior to the onset of 
his symptoms, making the true etiology of this case difficult to 
pinpoint; it is conceivable that the forearm may have simply 
been the first location to manifest dermatologic symptoms due 
to the pre-existing traumatic insult. The patient’s septicemia 
was likely secondary to, and not the cause of, his disease 
since he was otherwise healthy during the two weeks prior to 
seeking medical care, and the malodor noted is consistent with 
secondary bacterial infection of the necrotic tissue. Although 
there are other disorders with similar dermatologic appearance 
that could be considered, such as Staphylococcal scalded skin 
syndrome, this entity most commonly affects young children, 
and the biopsy report in this case was consistent with TEN.
Reported offending agents in TEN are diverse and most 
often pharmacologic. Although an uncommon disease, TEN 
carries a high rate of mortality, which has been shown to 
be decreased by early transfer to a burn care center. Early 
recognition of the disease and supportive care are the mainstays 
of emergency care. Available treatment modalities, both in the 
ED and in hospital, are limited and have variable efficacy, and 
antibiotics should be reserved for confirmed infections. 
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Table 1. SCORTEN Criteria
Risk Factors
•  Age > 40 years
•  Malignancy 
•  Total body surface area affected > 10%
•  Heart rate > 120 beats per minute
•  Serum Urea (blood urea nitrogen) > 28 mg/dL
•  Serum glucose > 250 mg/dL
•  Serum bicarbonate < 20 meq/L
Criteria Present  Mortality Rate





SCORTEN, SCORe of Toxic Epidermal Necrosis